{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:00:57Z","timestamp":1790787657625,"version":"4.1.0"},"reference-count":288,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T00:00:00Z","timestamp":1693699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T00:00:00Z","timestamp":1693699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s00392-023-02275-4","type":"journal-article","created":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T01:01:36Z","timestamp":1693702896000},"page":"1117-1136","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["The treatment of chronic anemia in heart failure: a global approach"],"prefix":"10.1007","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3689-9970","authenticated-orcid":false,"given":"Vittorio Emanuele","family":"Bianchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"von Haehling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,3]]},"reference":[{"issue":"11","key":"2275_CR1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0166635","volume":"11","author":"CH Le","year":"2016","unstructured":"Le CH (2016) The prevalence of anemia and moderate-severe anemia in the US population (NHANES 2003\u20132012). PLoS ONE 11(11):e0166635","journal-title":"PLoS ONE"},{"issue":"19","key":"2275_CR2","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1001\/archinte.165.19.2214","volume":"165","author":"NA Zakai","year":"2005","unstructured":"Zakai NA et al (2005) A prospective study of anemia status, hemoglobin concentration, and mortality in an elderly cohort: the Cardiovascular Health Study. Arch Intern Med 165(19):2214\u20132220","journal-title":"Arch Intern Med"},{"issue":"10","key":"2275_CR3","doi-asserted-by":"publisher","first-page":"3841","DOI":"10.1182\/blood-2005-10-4308","volume":"107","author":"BF Culleton","year":"2006","unstructured":"Culleton BF et al (2006) Impact of anemia on hospitalization and mortality in older adults. Blood 107(10):3841\u20133846","journal-title":"Blood"},{"issue":"5","key":"2275_CR4","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1182\/blood-2005-07-3046","volume":"107","author":"E Beutler","year":"2006","unstructured":"Beutler E, Waalen J (2006) The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration? Blood 107(5):1747\u20131750","journal-title":"Blood"},{"issue":"10","key":"2275_CR5","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1002\/clc.22181","volume":"36","author":"PA McCullough","year":"2013","unstructured":"McCullough PA et al (2013) Anemia and associated clinical outcomes in patients with heart failure due to reduced left ventricular systolic function. Clin Cardiol 36(10):611\u2013620","journal-title":"Clin Cardiol"},{"key":"2275_CR6","volume":"30","author":"K Chairat","year":"2020","unstructured":"Chairat K et al (2020) Relationship of anemia and clinical outcome in heart failure patients with preserved versus reduced ejection fraction in a rural area of Thailand. Int J Cardiol Heart Vasc 30:100597","journal-title":"Int J Cardiol Heart Vasc"},{"issue":"4","key":"2275_CR7","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jacc.2011.10.864","volume":"59","author":"B Waldum","year":"2012","unstructured":"Waldum B et al (2012) Baseline anemia is not a predictor of all-cause mortality in outpatients with advanced heart failure or severe renal dysfunction. Results from the Norwegian Heart Failure Registry. J Am Coll Cardiol 59(4):371\u2013378","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"2275_CR8","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1007\/s00392-016-1073-y","volume":"106","author":"S von Haehling","year":"2017","unstructured":"von Haehling S et al (2017) Prevalence and clinical impact of iron deficiency and anaemia among outpatients with chronic heart failure: the PrEP Registry. Clin Res Cardiol 106(6):436\u2013443","journal-title":"Clin Res Cardiol"},{"issue":"11","key":"2275_CR9","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1016\/S0735-1097(02)01854-5","volume":"39","author":"TB Horwich","year":"2002","unstructured":"Horwich TB et al (2002) Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol 39(11):1780\u20131786","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"2275_CR10","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1056\/NEJMoa020265","volume":"347","author":"D Levy","year":"2002","unstructured":"Levy D et al (2002) Long-term trends in the incidence of and survival with heart failure. N Engl J Med 347(18):1397\u20131402","journal-title":"N Engl J Med"},{"issue":"8","key":"2275_CR11","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1182\/blood-2004-05-1812","volume":"104","author":"JM Guralnik","year":"2004","unstructured":"Guralnik JM et al (2004) Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood 104(8):2263\u20132268","journal-title":"Blood"},{"issue":"3","key":"2275_CR12","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.amjcard.2017.04.043","volume":"120","author":"K Kajimoto","year":"2017","unstructured":"Kajimoto K et al (2017) Gender differences in anemia and survival in patients hospitalized for acute decompensated heart failure with preserved or reduced ejection fraction. Am J Cardiol 120(3):435\u2013442","journal-title":"Am J Cardiol"},{"issue":"10","key":"2275_CR13","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.jacc.2008.04.061","volume":"52","author":"HF Groenveld","year":"2008","unstructured":"Groenveld HF et al (2008) Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol 52(10):818\u2013827","journal-title":"J Am Coll Cardiol"},{"issue":"6\u20137","key":"2275_CR14","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.acvd.2013.04.004","volume":"106","author":"PV Ennezat","year":"2013","unstructured":"Ennezat PV et al (2013) Anaemia to predict outcome in patients with acute coronary syndromes. Arch Cardiovasc Dis 106(6\u20137):357\u2013365","journal-title":"Arch Cardiovasc Dis"},{"issue":"1","key":"2275_CR15","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12872-018-0785-5","volume":"18","author":"MG Colombo","year":"2018","unstructured":"Colombo MG et al (2018) Association between admission anemia and long-term mortality in patients with acute myocardial infarction: results from the MONICA\/KORA myocardial infarction registry. BMC Cardiovasc Disord 18(1):50","journal-title":"BMC Cardiovasc Disord"},{"issue":"5","key":"2275_CR16","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1093\/qjmed\/hcr258","volume":"105","author":"DS Ang","year":"2012","unstructured":"Ang DS et al (2012) The prognostic significance of early and late anaemia in acute coronary syndrome. QJM 105(5):445\u2013454","journal-title":"QJM"},{"issue":"11","key":"2275_CR17","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1093\/eurheartj\/ehp116","volume":"30","author":"SD Anker","year":"2009","unstructured":"Anker SD et al (2009) Prevalence, incidence, and prognostic value of anaemia in patients after an acute myocardial infarction: data from the OPTIMAAL trial. Eur Heart J 30(11):1331\u20131339","journal-title":"Eur Heart J"},{"issue":"3","key":"2275_CR18","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.hfc.2010.03.003","volume":"6","author":"EA Jankowska","year":"2010","unstructured":"Jankowska EA, Ponikowski P (2010) Molecular changes in myocardium in the course of anemia or iron deficiency. Heart Fail Clin 6(3):295\u2013304","journal-title":"Heart Fail Clin"},{"key":"2275_CR19","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ijcard.2019.08.049","volume":"298","author":"G Savarese","year":"2020","unstructured":"Savarese G et al (2020) Prevalence of, associations with, and prognostic role of anemia in heart failure across the ejection fraction spectrum. Int J Cardiol 298:59\u201365","journal-title":"Int J Cardiol"},{"issue":"1","key":"2275_CR20","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1177\/2047487318790823","volume":"26","author":"D Montero","year":"2019","unstructured":"Montero D, Haider T, Flammer AJ (2019) Erythropoietin response to anaemia in heart failure. Eur J Prev Cardiol 26(1):7\u201317","journal-title":"Eur J Prev Cardiol"},{"issue":"7","key":"2275_CR21","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.jacc.2008.04.044","volume":"52","author":"IS Anand","year":"2008","unstructured":"Anand IS (2008) Anemia and chronic heart failure implications and treatment options. J Am Coll Cardiol 52(7):501\u2013511","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"2275_CR22","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s10741-019-09891-1","volume":"25","author":"VE Bianchi","year":"2020","unstructured":"Bianchi VE (2020) Nutrition in chronic heart failure patients: a systematic review. Heart Fail Rev 25(6):1017\u20131026","journal-title":"Heart Fail Rev"},{"issue":"9","key":"2275_CR23","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/nrcardio.2011.77","volume":"8","author":"DJ van Veldhuisen","year":"2011","unstructured":"van Veldhuisen DJ et al (2011) Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches. Nat Rev Cardiol 8(9):485\u2013493","journal-title":"Nat Rev Cardiol"},{"issue":"16","key":"2275_CR24","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1161\/01.CIR.103.16.2055","volume":"103","author":"A Deswal","year":"2001","unstructured":"Deswal A et al (2001) Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 103(16):2055\u20132059","journal-title":"Circulation"},{"issue":"8","key":"2275_CR25","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1093\/gerona\/glr090","volume":"66","author":"AS Artz","year":"2011","unstructured":"Artz AS, Thirman MJ (2011) Unexplained anemia predominates despite an intensive evaluation in a racially diverse cohort of older adults from a referral anemia clinic. J Gerontol A Biol Sci Med Sci 66(8):925\u2013932","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"2","key":"2275_CR26","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.bcmd.2010.11.004","volume":"46","author":"EA Price","year":"2011","unstructured":"Price EA et al (2011) Anemia in older persons: etiology and evaluation. Blood Cells Mol Dis 46(2):159\u2013165","journal-title":"Blood Cells Mol Dis"},{"issue":"1","key":"2275_CR27","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/ajh.2830110106","volume":"11","author":"DA Lipschitz","year":"1981","unstructured":"Lipschitz DA, Mitchell CO, Thompson C (1981) The anemia of senescence. Am J Hematol 11(1):47\u201354","journal-title":"Am J Hematol"},{"issue":"3","key":"2275_CR28","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.cger.2019.03.002","volume":"35","author":"WB Ershler","year":"2019","unstructured":"Ershler WB (2019) Unexplained anemia in the elderly. Clin Geriatr Med 35(3):295\u2013305","journal-title":"Clin Geriatr Med"},{"issue":"8","key":"2275_CR29","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1111\/j.1532-5415.2005.53416.x","volume":"53","author":"WB Ershler","year":"2005","unstructured":"Ershler WB et al (2005) Serum erythropoietin and aging: a longitudinal analysis. J Am Geriatr Soc 53(8):1360\u20131365","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"2275_CR30","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1161\/01.CIR.0000134279.79571.73","volume":"110","author":"I Anand","year":"2004","unstructured":"Anand I et al (2004) Anemia and its relationship to clinical outcome in heart failure. Circulation 110(2):149\u2013154","journal-title":"Circulation"},{"issue":"4","key":"2275_CR31","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.semnephrol.2006.05.006","volume":"26","author":"DS Silverberg","year":"2006","unstructured":"Silverberg DS et al (2006) The interaction between heart failure and other heart diseases, renal failure, and anemia. Semin Nephrol 26(4):296\u2013306","journal-title":"Semin Nephrol"},{"issue":"3","key":"2275_CR32","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1249\/00005768-198406000-00010","volume":"16","author":"IL Kanstrup","year":"1984","unstructured":"Kanstrup IL, Ekblom B (1984) Blood volume and hemoglobin concentration as determinants of maximal aerobic power. Med Sci Sports Exerc 16(3):256\u2013262","journal-title":"Med Sci Sports Exerc"},{"issue":"1","key":"2275_CR33","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1139\/h99-006","volume":"24","author":"N Gledhill","year":"1999","unstructured":"Gledhill N, Warburton D, Jamnik V (1999) Haemoglobin, blood volume, cardiac function, and aerobic power. Can J Appl Physiol 24(1):54\u201365","journal-title":"Can J Appl Physiol"},{"issue":"1","key":"2275_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0190645","volume":"13","author":"AS Wedell-Neergaard","year":"2018","unstructured":"Wedell-Neergaard AS et al (2018) Low fitness is associated with abdominal adiposity and low-grade inflammation independent of BMI. PLoS ONE 13(1):e0190645","journal-title":"PLoS ONE"},{"issue":"7","key":"2275_CR35","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1093\/eurheartj\/ehs381","volume":"34","author":"S Fulster","year":"2013","unstructured":"Fulster S et al (2013) Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF). Eur Heart J 34(7):512\u2013519","journal-title":"Eur Heart J"},{"issue":"10369","key":"2275_CR36","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1016\/S0140-6736(22)02083-9","volume":"400","author":"PR Kalra","year":"2023","unstructured":"Kalra PR et al (2023) Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet 400(10369):2199\u20132209","journal-title":"Lancet"},{"issue":"31","key":"2275_CR37","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1093\/eurheartj\/ehab234","volume":"42","author":"EA Jankowska","year":"2021","unstructured":"Jankowska EA et al (2021) The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study. Eur Heart J 42(31):3011\u20133020","journal-title":"Eur Heart J"},{"issue":"5","key":"2275_CR38","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.008100","volume":"14","author":"RJ Mentz","year":"2021","unstructured":"Mentz RJ et al (2021) Randomized placebo-controlled trial of ferric carboxymaltose in heart failure with iron deficiency: rationale and design. Circ Heart Fail 14(5):e008100","journal-title":"Circ Heart Fail"},{"issue":"10266","key":"2275_CR39","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1016\/S0140-6736(20)32339-4","volume":"396","author":"P Ponikowski","year":"2020","unstructured":"Ponikowski P et al (2020) Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet 396(10266):1895\u20131904","journal-title":"Lancet"},{"issue":"7","key":"2275_CR40","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1177\/0300060519847352","volume":"47","author":"SC Zdravkovic","year":"2019","unstructured":"Zdravkovic SC et al (2019) Effects of 6-months of oral ferrous and ferric supplement therapy in patients who were hospitalized for decompensated chronic heart failure. J Int Med Res 47(7):3179\u20133189","journal-title":"J Int Med Res"},{"issue":"1","key":"2275_CR41","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1093\/eurheartj\/ehr504","volume":"34","author":"J Comin-Colet","year":"2013","unstructured":"Comin-Colet J et al (2013) The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study. Eur Heart J 34(1):30\u201338","journal-title":"Eur Heart J"},{"issue":"5","key":"2275_CR42","first-page":"488","volume":"369","author":"K Swedberg","year":"2013","unstructured":"Swedberg K, McMurray JJ, Young JB (2013) Darbepoetin alfa in systolic heart failure. N Engl J Med 369(5):488\u2013489","journal-title":"N Engl J Med"},{"issue":"7","key":"2275_CR43","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1093\/eurjhf\/hft068","volume":"15","author":"EM Van Craenenbroeck","year":"2013","unstructured":"Van Craenenbroeck EM et al (2013) The effect of intravenous ferric carboxymaltose on red cell distribution width: a subanalysis of the FAIR-HF study. Eur J Heart Fail 15(7):756\u2013762","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"2275_CR44","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1093\/eurjhf\/hfp098","volume":"11","author":"JJ McMurray","year":"2009","unstructured":"McMurray JJ et al (2009) Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial. Eur J Heart Fail 11(8):795\u2013801","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"2275_CR45","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1161\/CIRCHEARTFAILURE.112.969717","volume":"6","author":"MS Maurer","year":"2013","unstructured":"Maurer MS et al (2013) Treating anemia in older adults with heart failure with a preserved ejection fraction with epoetin alfa: single-blind randomized clinical trial of safety and efficacy. Circ Heart Fail 6(2):254\u2013263","journal-title":"Circ Heart Fail"},{"issue":"3","key":"2275_CR46","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/j.1751-7133.2010.00142.x","volume":"16","author":"WT Abraham","year":"2010","unstructured":"Abraham WT et al (2010) Treatment of anemia with darbepoetin alfa in heart failure. Congest Heart Fail 16(3):87\u201395","journal-title":"Congest Heart Fail"},{"issue":"21","key":"2275_CR47","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","volume":"361","author":"MA Pfeffer","year":"2009","unstructured":"Pfeffer MA et al (2009) A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361(21):2019\u20132032","journal-title":"N Engl J Med"},{"issue":"11","key":"2275_CR48","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1093\/eurjhf\/hfp140","volume":"11","author":"SD Anker","year":"2009","unstructured":"Anker SD et al (2009) Rationale and design of Ferinject assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia. Eur J Heart Fail 11(11):1084\u20131091","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"2275_CR49","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1161\/CIRCULATIONAHA.107.698514","volume":"117","author":"JK Ghali","year":"2008","unstructured":"Ghali JK et al (2008) Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation 117(4):526\u2013535","journal-title":"Circulation"},{"issue":"18","key":"2275_CR50","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1093\/eurheartj\/ehm328","volume":"28","author":"DJ van Veldhuisen","year":"2007","unstructured":"van Veldhuisen DJ et al (2007) Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. Eur Heart J 28(18):2208\u20132216","journal-title":"Eur Heart J"},{"issue":"1","key":"2275_CR51","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/ndt\/18.1.141","volume":"18","author":"DS Silverberg","year":"2003","unstructured":"Silverberg DS et al (2003) The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant 18(1):141\u2013146","journal-title":"Nephrol Dial Transplant"},{"issue":"10369","key":"2275_CR52","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1016\/S0140-6736(22)02083-9","volume":"400","author":"PR Kalra","year":"2022","unstructured":"Kalra PR et al (2022) Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet 400(10369):2199\u20132209","journal-title":"Lancet"},{"issue":"48","key":"2275_CR53","doi-asserted-by":"publisher","first-page":"4915","DOI":"10.1093\/eurheartj\/ehab624","volume":"42","author":"EA Jankowska","year":"2021","unstructured":"Jankowska EA, Ponikowski P (2021) Intravenous iron supplementation: novel anti-remodelling therapy for patients with heart failure? Eur Heart J 42(48):4915\u20134918","journal-title":"Eur Heart J"},{"issue":"25","key":"2275_CR54","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","volume":"361","author":"SD Anker","year":"2009","unstructured":"Anker SD et al (2009) Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 361(25):2436\u20132448","journal-title":"N Engl J Med"},{"issue":"13","key":"2275_CR55","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1056\/NEJMoa1214865","volume":"368","author":"K Swedberg","year":"2013","unstructured":"Swedberg K et al (2013) Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med 368(13):1210\u20131219","journal-title":"N Engl J Med"},{"issue":"5","key":"2275_CR56","first-page":"337","volume":"5","author":"DS Silverberg","year":"2003","unstructured":"Silverberg DS et al (2003) Effect of correction of anemia with erythropoietin and intravenous iron in resistant heart failure in octogenarians. Isr Med Assoc J 5(5):337\u2013339","journal-title":"Isr Med Assoc J"},{"issue":"15","key":"2275_CR57","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1093\/eurheartj\/ehq158","volume":"31","author":"EA Jankowska","year":"2010","unstructured":"Jankowska EA et al (2010) Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J 31(15):1872\u20131880","journal-title":"Eur Heart J"},{"issue":"10","key":"2275_CR58","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1007\/s00277-019-03777-w","volume":"98","author":"R Mistry","year":"2019","unstructured":"Mistry R et al (2019) Iron deficiency in heart failure, an underdiagnosed and undertreated condition during hospitalization. Ann Hematol 98(10):2293\u20132297","journal-title":"Ann Hematol"},{"issue":"5","key":"2275_CR59","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1002\/ejhf.1154","volume":"20","author":"MF Hoes","year":"2018","unstructured":"Hoes MF et al (2018) Iron deficiency impairs contractility of human cardiomyocytes through decreased mitochondrial function. Eur J Heart Fail 20(5):910\u2013919","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"2275_CR60","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1097\/HJH.0000000000000547","volume":"33","author":"Y Naito","year":"2015","unstructured":"Naito Y et al (2015) Cardiac remodeling in response to chronic iron deficiency: role of the erythropoietin receptor. J Hypertens 33(6):1267\u20131275","journal-title":"J Hypertens"},{"key":"2275_CR61","doi-asserted-by":"publisher","first-page":"44460","DOI":"10.1038\/srep44460","volume":"7","author":"S Wongjaikam","year":"2017","unstructured":"Wongjaikam S et al (2017) Restoring the impaired cardiac calcium homeostasis and cardiac function in iron overload rats by the combined deferiprone and N-acetyl cysteine. Sci Rep 7:44460","journal-title":"Sci Rep"},{"issue":"3","key":"2275_CR62","first-page":"194","volume":"18","author":"Q Zhou","year":"2017","unstructured":"Zhou Q et al (2017) Assessment of left ventricular systolic function in patients with iron deficiency anemia by three-dimensional speckle-tracking echocardiography. Anatol J Cardiol 18(3):194\u2013199","journal-title":"Anatol J Cardiol"},{"issue":"3","key":"2275_CR63","doi-asserted-by":"publisher","first-page":"H585","DOI":"10.1152\/ajpheart.00463.2008","volume":"296","author":"Y Naito","year":"2009","unstructured":"Naito Y et al (2009) Adaptive response of the heart to long-term anemia induced by iron deficiency. Am J Physiol Heart Circ Physiol 296(3):H585\u2013H593","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"11","key":"2275_CR64","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1001\/archinte.165.11.1304","volume":"165","author":"J George","year":"2005","unstructured":"George J et al (2005) Circulating erythropoietin levels and prognosis in patients with congestive heart failure: comparison with neurohormonal and inflammatory markers. Arch Intern Med 165(11):1304\u20131309","journal-title":"Arch Intern Med"},{"issue":"12","key":"2275_CR65","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1016\/j.jacc.2011.04.040","volume":"58","author":"DO Okonko","year":"2011","unstructured":"Okonko DO et al (2011) Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival. J Am Coll Cardiol 58(12):1241\u20131251","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"2275_CR66","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/clc.22956","volume":"41","author":"G Minana","year":"2018","unstructured":"Minana G et al (2018) Changes in myocardial iron content following administration of intravenous iron (Myocardial-IRON): study design. Clin Cardiol 41(6):729\u2013735","journal-title":"Clin Cardiol"},{"issue":"2","key":"2275_CR67","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1080\/00015385.2017.1351239","volume":"73","author":"P Martens","year":"2018","unstructured":"Martens P et al (2018) Impact of iron deficiency on exercise capacity and outcome in heart failure with reduced, mid-range and preserved ejection fraction. Acta Cardiol 73(2):115\u2013123","journal-title":"Acta Cardiol"},{"issue":"4","key":"2275_CR68","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.014254","volume":"9","author":"J Nunez","year":"2020","unstructured":"Nunez J et al (2020) Noninvasive imaging estimation of myocardial iron repletion following administration of intravenous iron: the myocardial-IRON trial. J Am Heart Assoc 9(4):e014254","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"2275_CR69","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00392-018-1327-y","volume":"108","author":"H Wienbergen","year":"2019","unstructured":"Wienbergen H et al (2019) Long-term effects of iron deficiency in patients with heart failure with or without anemia: the RAID-HF follow-up study. Clin Res Cardiol 108(1):93\u2013100","journal-title":"Clin Res Cardiol"},{"issue":"8","key":"2275_CR70","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1017\/S000711451900014X","volume":"121","author":"S Zhang","year":"2019","unstructured":"Zhang S et al (2019) Efficacy and safety of iron supplementation in patients with heart failure and iron deficiency: a meta-analysis. Br J Nutr 121(8):841\u2013848","journal-title":"Br J Nutr"},{"issue":"Suppl 1","key":"2275_CR71","first-page":"S83","volume":"21","author":"M Auerbach","year":"2017","unstructured":"Auerbach M, Macdougall I (2017) The available intravenous iron formulations: history, efficacy, and toxicology. Hemodial Int 21(Suppl 1):S83\u2013S92","journal-title":"Hemodial Int"},{"issue":"4","key":"2275_CR72","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1056\/NEJMra1004967","volume":"366","author":"RE Fleming","year":"2012","unstructured":"Fleming RE, Ponka P (2012) Iron overload in human disease. N Engl J Med 366(4):348\u2013359","journal-title":"N Engl J Med"},{"issue":"2","key":"2275_CR73","doi-asserted-by":"publisher","first-page":"386","DOI":"10.2215\/CJN.02840608","volume":"4","author":"R Provenzano","year":"2009","unstructured":"Provenzano R et al (2009) Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin J Am Soc Nephrol 4(2):386\u2013393","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"2275_CR74","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1093\/ndt\/gfq613","volume":"26","author":"WY Qunibi","year":"2011","unstructured":"Qunibi WY et al (2011) A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients. Nephrol Dial Transplant 26(5):1599\u20131607","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"2275_CR75","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1111\/j.1572-0241.2005.00250.x","volume":"100","author":"O Schroder","year":"2005","unstructured":"Schroder O et al (2005) Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease\u2014a randomized, controlled, open-label, multicenter study. Am J Gastroenterol 100(11):2503\u20132509","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"2275_CR76","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/ajh.21656","volume":"85","author":"M Lu","year":"2010","unstructured":"Lu M et al (2010) FDA report: ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. Am J Hematol 85(5):315\u2013319","journal-title":"Am J Hematol"},{"issue":"2","key":"2275_CR77","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/trf.12289","volume":"54","author":"JE Onken","year":"2014","unstructured":"Onken JE et al (2014) A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia. Transfusion 54(2):306\u2013315","journal-title":"Transfusion"},{"issue":"6","key":"2275_CR78","doi-asserted-by":"publisher","first-page":"739","DOI":"10.2165\/00003495-200969060-00007","volume":"69","author":"KA Lyseng-Williamson","year":"2009","unstructured":"Lyseng-Williamson KA, Keating GM (2009) Ferric carboxymaltose: a review of its use in iron-deficiency anaemia. Drugs 69(6):739\u2013756","journal-title":"Drugs"},{"issue":"6","key":"2275_CR79","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/j.jacc.2006.07.015","volume":"48","author":"AP Bolger","year":"2006","unstructured":"Bolger AP et al (2006) Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol 48(6):1225\u20131227","journal-title":"J Am Coll Cardiol"},{"key":"2275_CR80","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.amjcard.2021.04.042","volume":"152","author":"AP Ambrosy","year":"2021","unstructured":"Ambrosy AP et al (2021) Safety and efficacy of intravenous ferric derisomaltose compared to iron sucrose for iron deficiency anemia in patients with chronic kidney disease with and without heart failure. Am J Cardiol 152:138\u2013145","journal-title":"Am J Cardiol"},{"issue":"4","key":"2275_CR81","first-page":"310","volume":"20","author":"MJ Laso-Morales","year":"2022","unstructured":"Laso-Morales MJ et al (2022) Single-dose intravenous ferric carboxymaltose infusion versus multiple fractionated doses of intravenous iron sucrose in the treatment of post-operative anaemia in colorectal cancer patients: a randomised controlled trial. Blood Transfus 20(4):310\u2013318","journal-title":"Blood Transfus"},{"issue":"4 Suppl 2","key":"2275_CR82","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1053\/ajkd.1999.v34.aajkd0344b0047","volume":"34","author":"S Fishbane","year":"1999","unstructured":"Fishbane S (1999) Review of issues relating to iron and infection. Am J Kidney Dis 34(4 Suppl 2):S47-52","journal-title":"Am J Kidney Dis"},{"key":"2275_CR83","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f4822","volume":"347","author":"E Litton","year":"2013","unstructured":"Litton E, Xiao J, Ho KM (2013) Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomised clinical trials. BMJ 347:f4822","journal-title":"BMJ"},{"issue":"9","key":"2275_CR84","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1345\/aph.1K187","volume":"41","author":"L Maynor","year":"2007","unstructured":"Maynor L, Brophy DF (2007) Risk of infection with intravenous iron therapy. Ann Pharmacother 41(9):1476\u20131480","journal-title":"Ann Pharmacother"},{"issue":"4","key":"2275_CR85","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1089\/sur.2006.7.361","volume":"7","author":"S Torres","year":"2006","unstructured":"Torres S et al (2006) Intravenous iron following cardiac surgery does not increase the infection rate. Surg Infect (Larchmt) 7(4):361\u2013366","journal-title":"Surg Infect (Larchmt)"},{"key":"2275_CR86","first-page":"11:4","volume":"24","author":"RA Moore","year":"2011","unstructured":"Moore RA et al (2011) Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data. BMC Blood Disord. 24; 11:4","journal-title":"BMC Blood Disord"},{"issue":"1","key":"2275_CR87","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3109\/0284186X.2012.702921","volume":"52","author":"A Gafter-Gvili","year":"2013","unstructured":"Gafter-Gvili A et al (2013) Intravenous iron supplementation for the treatment of chemotherapy-induced anaemia\u2014systematic review and meta-analysis of randomised controlled trials. Acta Oncol 52(1):18\u201329","journal-title":"Acta Oncol"},{"issue":"4","key":"2275_CR88","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1002\/cphy.c100075","volume":"1","author":"RH Wenger","year":"2011","unstructured":"Wenger RH, Kurtz A (2011) Erythropoietin. Compr Physiol 1(4):1759\u20131794","journal-title":"Compr Physiol"},{"issue":"Pt 6","key":"2275_CR89","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1113\/jphysiol.2010.195057","volume":"589","author":"W Jelkmann","year":"2011","unstructured":"Jelkmann W (2011) Regulation of erythropoietin production. J Physiol 589(Pt 6):1251\u20131258","journal-title":"J Physiol"},{"issue":"9","key":"2275_CR90","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1096\/fj.03-1289fje","volume":"18","author":"GL Wright","year":"2004","unstructured":"Wright GL et al (2004) Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury. FASEB J 18(9):1031\u20131033","journal-title":"FASEB J"},{"issue":"23","key":"2275_CR91","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/j.jacc.2010.04.068","volume":"56","author":"A Ogino","year":"2010","unstructured":"Ogino A et al (2010) Erythropoietin receptor signaling mitigates renal dysfunction-associated heart failure by mechanisms unrelated to relief of anemia. J Am Coll Cardiol 56(23):1949\u20131958","journal-title":"J Am Coll Cardiol"},{"key":"2275_CR92","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.resp.2019.05.012","volume":"267","author":"EM Schneider Gasser","year":"2019","unstructured":"Schneider Gasser EM et al (2019) Developmental expression patterns of erythropoietin and its receptor in mouse brainstem respiratory regions. Respir Physiol Neurobiol 267:12\u201319","journal-title":"Respir Physiol Neurobiol"},{"issue":"7","key":"2275_CR93","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1172\/JCI18200","volume":"112","author":"CJ Parsa","year":"2003","unstructured":"Parsa CJ et al (2003) A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 112(7):999\u20131007","journal-title":"J Clin Invest"},{"issue":"4","key":"2275_CR94","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/j.1582-4934.2008.00546.x","volume":"13","author":"C Klopsch","year":"2009","unstructured":"Klopsch C et al (2009) Intracardiac injection of erythropoietin induces stem cell recruitment and improves cardiac functions in a rat myocardial infarction model. J Cell Mol Med 13(4):664\u2013679","journal-title":"J Cell Mol Med"},{"issue":"2","key":"2275_CR95","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s40119-018-0122-1","volume":"7","author":"M Orii","year":"2018","unstructured":"Orii M et al (2018) Effect of erythropoietin administration on myocardial viability and coronary microvascular dysfunction in anterior acute myocardial infarction: randomized controlled trial in the Japanese population. Cardiol Ther 7(2):151\u2013162","journal-title":"Cardiol Ther"},{"issue":"2","key":"2275_CR96","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1096\/fj.08-109462","volume":"23","author":"S Brunner","year":"2009","unstructured":"Brunner S et al (2009) Erythropoietin administration after myocardial infarction in mice attenuates ischemic cardiomyopathy associated with enhanced homing of bone marrow-derived progenitor cells via the CXCR-4\/SDF-1 axis. FASEB J 23(2):351\u2013361","journal-title":"FASEB J"},{"issue":"4","key":"2275_CR97","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1097\/01.crd.0000195223.85556.8e","volume":"14","author":"ME Guglin","year":"2006","unstructured":"Guglin ME, Koul D (2006) Cardiovascular effects of erythropoietin: anemia and beyond. Cardiol Rev 14(4):200\u2013204","journal-title":"Cardiol Rev"},{"key":"2275_CR98","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/1475-2840-11-105","volume":"11","author":"J Lu","year":"2012","unstructured":"Lu J et al (2012) Erythropoietin attenuates cardiac dysfunction by increasing myocardial angiogenesis and inhibiting interstitial fibrosis in diabetic rats. Cardiovasc Diabetol 7;11:105","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"2275_CR99","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1080\/10520295.2018.1443347","volume":"93","author":"A Guven Bagla","year":"2018","unstructured":"Guven Bagla A et al (2018) Changes in kidney tissue and effects of erythropoietin after acute heart failure. Biotech Histochem 93(5):340\u2013353","journal-title":"Biotech Histochem"},{"issue":"16","key":"2275_CR100","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1093\/eurheartj\/ehm177","volume":"28","author":"BD Westenbrink","year":"2007","unstructured":"Westenbrink BD et al (2007) Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. Eur Heart J 28(16):2018\u20132027","journal-title":"Eur Heart J"},{"issue":"2A","key":"2275_CR101","doi-asserted-by":"publisher","first-page":"4S","DOI":"10.1016\/S0002-9343(96)00160-X","volume":"101","author":"JW Adamson","year":"1996","unstructured":"Adamson JW (1996) Regulation of red blood cell production. Am J Med 101(2A):4S-6S","journal-title":"Am J Med"},{"issue":"2","key":"2275_CR102","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1161\/01.CIR.0000044914.42696.6A","volume":"107","author":"DM Mancini","year":"2003","unstructured":"Mancini DM et al (2003) Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 107(2):294\u2013299","journal-title":"Circulation"},{"issue":"7","key":"2275_CR103","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1016\/S0735-1097(00)00613-6","volume":"35","author":"DS Silverberg","year":"2000","unstructured":"Silverberg DS et al (2000) The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 35(7):1737\u20131744","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"2275_CR104","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1016\/S0735-1097(01)01248-7","volume":"37","author":"DS Silverberg","year":"2001","unstructured":"Silverberg DS et al (2001) The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 37(7):1775\u20131780","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"2275_CR105","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.ahj.2011.02.013","volume":"161","author":"D Kotecha","year":"2011","unstructured":"Kotecha D et al (2011) Erythropoietin as a treatment of anemia in heart failure: systematic review of randomized trials. Am Heart J 161(5):822-831e2","journal-title":"Am Heart J"},{"key":"2275_CR106","volume":"1","author":"K Ngo","year":"2010","unstructured":"Ngo K et al (2010) Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients. Cochrane Database Syst Rev 1:CD007613","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"2275_CR107","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.jacc.2006.11.024","volume":"49","author":"P Ponikowski","year":"2007","unstructured":"Ponikowski P et al (2007) Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 49(7):753\u2013762","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"2275_CR108","doi-asserted-by":"publisher","first-page":"751e1","DOI":"10.1016\/j.ahj.2008.01.016","volume":"155","author":"JT Parissis","year":"2008","unstructured":"Parissis JT et al (2008) Effects of darbepoetin alpha on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am Heart J 155(4):751e1-757","journal-title":"Am Heart J"},{"issue":"3","key":"2275_CR109","doi-asserted-by":"publisher","first-page":"863","DOI":"10.3892\/etm.2014.1845","volume":"8","author":"S Zhou","year":"2014","unstructured":"Zhou S et al (2014) Protective roles of erythropoiesis-stimulating proteins in chronic heart failure with anemia. Exp Ther Med 8(3):863\u2013870","journal-title":"Exp Ther Med"},{"issue":"1","key":"2275_CR110","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/1074248414541841","volume":"20","author":"DE Lindquist","year":"2015","unstructured":"Lindquist DE, Cruz JL, Brown JN (2015) Use of erythropoiesis-stimulating agents in the treatment of anemia in patients with systolic heart failure. J Cardiovasc Pharmacol Ther 20(1):59\u201365","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"4","key":"2275_CR111","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/chf.12027","volume":"19","author":"P Green","year":"2013","unstructured":"Green P et al (2013) Impact of epoetin alfa on left ventricular structure, function, and pressure volume relations as assessed by cardiac magnetic resonance: the heart failure preserved ejection fraction (HFPEF) anemia trial. Congest Heart Fail 19(4):172\u2013179","journal-title":"Congest Heart Fail"},{"issue":"3","key":"2275_CR112","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1159\/000085881","volume":"25","author":"H Hampl","year":"2005","unstructured":"Hampl H et al (2005) Effects of optimized heart failure therapy and anemia correction with epoetin beta on left ventricular mass in hemodialysis patients. Am J Nephrol 25(3):211\u2013220","journal-title":"Am J Nephrol"},{"issue":"10113","key":"2275_CR113","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1016\/S0140-6736(17)31634-3","volume":"390","author":"SA Lear","year":"2017","unstructured":"Lear SA et al (2017) The effect of physical activity on mortality and cardiovascular disease in 130 000 people from 17 high-income, middle-income, and low-income countries: the PURE study. Lancet 390(10113):2643\u20132654","journal-title":"Lancet"},{"issue":"14","key":"2275_CR114","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1016\/j.jacc.2017.08.017","volume":"70","author":"RAH Stewart","year":"2017","unstructured":"Stewart RAH et al (2017) Physical activity and mortality in patients with stable coronary heart disease. J Am Coll Cardiol 70(14):1689\u20131700","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"2275_CR115","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1093\/eurjhf\/hfp130","volume":"11","author":"M Klapholz","year":"2009","unstructured":"Klapholz M et al (2009) The safety and tolerability of darbepoetin alfa in patients with anaemia and symptomatic heart failure. Eur J Heart Fail 11(11):1071\u20131077","journal-title":"Eur J Heart Fail"},{"key":"2275_CR116","doi-asserted-by":"publisher","first-page":"641","DOI":"10.2147\/TCRM.S61551","volume":"10","author":"A Palazzuoli","year":"2014","unstructured":"Palazzuoli A et al (2014) The role of erythropoietin stimulating agents in anemic patients with heart failure: solved and unresolved questions. Ther Clin Risk Manag 10:641\u2013650","journal-title":"Ther Clin Risk Manag"},{"key":"2275_CR117","volume":"8","author":"B Mesgarpour","year":"2017","unstructured":"Mesgarpour B et al (2017) Harms of off-label erythropoiesis-stimulating agents for critically ill people. Cochrane Database Syst Rev\u00a025;8:CD010969","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"2275_CR118","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1515\/jbcpp-2016-0102","volume":"29","author":"KK Zahidova","year":"2018","unstructured":"Zahidova KK (2018) Indexes of the erythropoietin level in the blood plasma of chronic heart failure patients with anemia. J Basic Clin Physiol Pharmacol 29(1):11\u201317","journal-title":"J Basic Clin Physiol Pharmacol"},{"issue":"7","key":"2275_CR119","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/ejhf.537","volume":"18","author":"T Nagai","year":"2016","unstructured":"Nagai T et al (2016) Prognostic significance of endogenous erythropoietin in long-term outcome of patients with acute decompensated heart failure. Eur J Heart Fail 18(7):803\u2013813","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"2275_CR120","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1093\/eurheartj\/ehn205","volume":"29","author":"P van der Meer","year":"2008","unstructured":"van der Meer P et al (2008) Adequacy of endogenous erythropoietin levels and mortality in anaemic heart failure patients. Eur Heart J 29(12):1510\u20131515","journal-title":"Eur Heart J"},{"issue":"5","key":"2275_CR121","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.3892\/etm.2013.1307","volume":"6","author":"L Guo","year":"2013","unstructured":"Guo L et al (2013) Serum erythropoietin level predicts the prognosis of chronic heart failure with or without anemia. Exp Ther Med 6(5):1327\u20131331","journal-title":"Exp Ther Med"},{"issue":"1","key":"2275_CR122","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.115.002124","volume":"9","author":"PS Garimella","year":"2016","unstructured":"Garimella PS et al (2016) Association of serum erythropoietin with cardiovascular events, kidney function decline, and mortality: the health aging and body composition study. Circ Heart Fail 9(1):e002124","journal-title":"Circ Heart Fail"},{"issue":"5","key":"2275_CR123","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/0002-9149(94)90905-9","volume":"74","author":"M Volpe","year":"1994","unstructured":"Volpe M et al (1994) Blood levels of erythropoietin in congestive heart failure and correlation with clinical, hemodynamic, and hormonal profiles. Am J Cardiol 74(5):468\u2013473","journal-title":"Am J Cardiol"},{"issue":"1","key":"2275_CR124","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jacc.2004.03.052","volume":"44","author":"P van der Meer","year":"2004","unstructured":"van der Meer P et al (2004) Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. J Am Coll Cardiol 44(1):63\u201367","journal-title":"J Am Coll Cardiol"},{"key":"2275_CR125","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ijcard.2016.04.187","volume":"218","author":"J Kang","year":"2016","unstructured":"Kang J et al (2016) The effects of erythropoiesis stimulating therapy for anemia in chronic heart failure: a meta-analysis of randomized clinical trials. Int J Cardiol 218:12\u201322","journal-title":"Int J Cardiol"},{"issue":"3","key":"2275_CR126","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.ijcard.2011.07.045","volume":"164","author":"DO Okonko","year":"2013","unstructured":"Okonko DO et al (2013) Erythropoietin resistance contributes to anaemia in chronic heart failure and relates to aberrant JAK-STAT signal transduction. Int J Cardiol 164(3):359\u2013364","journal-title":"Int J Cardiol"},{"issue":"1","key":"2275_CR127","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.tem.2017.11.001","volume":"29","author":"DW Dodington","year":"2018","unstructured":"Dodington DW, Desai HR, Woo M (2018) JAK\/STAT\u2014emerging players in metabolism. Trends Endocrinol Metab 29(1):55\u201365","journal-title":"Trends Endocrinol Metab"},{"issue":"2","key":"2275_CR128","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/j.1525-139X.2006.00141.x","volume":"19","author":"C Kwack","year":"2006","unstructured":"Kwack C, Balakrishnan VS (2006) Managing erythropoietin hyporesponsiveness. Semin Dial 19(2):146\u2013151","journal-title":"Semin Dial"},{"issue":"2","key":"2275_CR129","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ejim.2013.12.011","volume":"25","author":"NR Robles","year":"2014","unstructured":"Robles NR, Macias JF, Herrera J (2014) Erythropoiesis stimulating agents (ESAs) for congestive heart failure: the red and the black. Eur J Intern Med 25(2):193\u2013196","journal-title":"Eur J Intern Med"},{"issue":"14","key":"2275_CR130","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.3390\/ijms20143552","volume":"20","author":"M Saotome","year":"2019","unstructured":"Saotome M et al (2019) Cardiac insulin resistance in heart failure: the role of mitochondrial dynamics. Int J Mol Sci 20(14):3552","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2275_CR131","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1002\/ehf2.13384","volume":"8","author":"S Schafer","year":"2021","unstructured":"Schafer S et al (2021) Low testosterone concentrations and prediction of future heart failure in men and in women: evidence from the large FINRISK97 study. ESC Heart Fail 8(4):2485\u20132491","journal-title":"ESC Heart Fail"},{"issue":"2","key":"2275_CR132","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/ehf2.12225","volume":"5","author":"G Cattadori","year":"2018","unstructured":"Cattadori G et al (2018) Exercise and heart failure: an update. ESC Heart Fail 5(2):222\u2013232","journal-title":"ESC Heart Fail"},{"issue":"6","key":"2275_CR133","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1097\/FJC.0b013e3181a6ac38","volume":"53","author":"A Palazzuoli","year":"2009","unstructured":"Palazzuoli A et al (2009) Beta-erythropoietin effects on ventricular remodeling, left and right systolic function, pulmonary pressure, and hospitalizations in patients affected with heart failure and anemia. J Cardiovasc Pharmacol 53(6):462\u2013467","journal-title":"J Cardiovasc Pharmacol"},{"issue":"1","key":"2275_CR134","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1080\/00913847.2018.1402663","volume":"46","author":"P Sgro","year":"2018","unstructured":"Sgro P et al (2018) Effects of erythropoietin abuse on exercise performance. Phys Sportsmed 46(1):105\u2013115","journal-title":"Phys Sportsmed"},{"issue":"2","key":"2275_CR135","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1249\/MSS.0000000000001777","volume":"51","author":"DW Haile","year":"2019","unstructured":"Haile DW et al (2019) Effects of EPO on blood parameters and running performance in Kenyan athletes. Med Sci Sports Exerc 51(2):299\u2013307","journal-title":"Med Sci Sports Exerc"},{"issue":"2","key":"2275_CR136","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0056151","volume":"8","author":"J Durussel","year":"2013","unstructured":"Durussel J et al (2013) Haemoglobin mass and running time trial performance after recombinant human erythropoietin administration in trained men. PLoS ONE 8(2):e56151","journal-title":"PLoS ONE"},{"issue":"1","key":"2275_CR137","doi-asserted-by":"publisher","DOI":"10.1136\/bmjsem-2019-000716","volume":"6","author":"KV Trinh","year":"2020","unstructured":"Trinh KV et al (2020) Effect of erythropoietin on athletic performance: a systematic review and meta-analysis. BMJ Open Sport Exerc Med 6(1):e000716","journal-title":"BMJ Open Sport Exerc Med"},{"issue":"8","key":"2275_CR138","doi-asserted-by":"publisher","first-page":"e374","DOI":"10.1016\/S2352-3026(17)30105-9","volume":"4","author":"J Heuberger","year":"2017","unstructured":"Heuberger J et al (2017) Effects of erythropoietin on cycling performance of well trained cyclists: a double-blind, randomised, placebo-controlled trial. Lancet Haematol 4(8):e374\u2013e386","journal-title":"Lancet Haematol"},{"issue":"3","key":"2275_CR139","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1053\/j.ajkd.2009.12.018","volume":"55","author":"KL Johansen","year":"2010","unstructured":"Johansen KL et al (2010) Systematic review and meta-analysis of exercise tolerance and physical functioning in dialysis patients treated with erythropoiesis-stimulating agents. Am J Kidney Dis 55(3):535\u2013548","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"2275_CR140","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.cardfail.2008.10.024","volume":"15","author":"SA Timmer","year":"2009","unstructured":"Timmer SA et al (2009) The potential role of erythropoietin in chronic heart failure: from the correction of anemia to improved perfusion and reduced apoptosis? J Card Fail 15(4):353\u2013361","journal-title":"J Card Fail"},{"issue":"2","key":"2275_CR141","first-page":"112","volume":"43","author":"T Santoso","year":"2011","unstructured":"Santoso T et al (2011) Safety and feasibility of combined granulocyte colony stimulating factor and erythropoetin based-stem cell therapy using intracoronary infusion of peripheral blood stem cells in patients with recent anterior myocardial infarction: one-year follow-up of a phase 1 study. Acta Med Indones 43(2):112\u2013121","journal-title":"Acta Med Indones"},{"issue":"6","key":"2275_CR142","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11886-018-0978-7","volume":"20","author":"B Bozkurt","year":"2018","unstructured":"Bozkurt B (2018) What is new in heart failure management in 2017? Update on ACC\/AHA heart failure guidelines. Curr Cardiol Rep 20(6):39","journal-title":"Curr Cardiol Rep"},{"issue":"1","key":"2275_CR143","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/ejhf.2333","volume":"24","author":"M Authors\/Task Force","year":"2022","unstructured":"Authors\/Task Force M et al (2022) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 24(1):4\u2013131","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"2275_CR144","first-page":"749","volume":"17","author":"DS Silverberg","year":"2004","unstructured":"Silverberg DS, Wexler D, Iaina A (2004) The role of anemia in the progression of congestive heart failure. Is there a place for erythropoietin and intravenous iron? J Nephrol 17(6):749\u2013761","journal-title":"J Nephrol"},{"issue":"1","key":"2275_CR145","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1177\/0003319708316169","volume":"60","author":"ED Pagourelias","year":"2009","unstructured":"Pagourelias ED et al (2009) Cardiorenal anemia syndrome: do erythropoietin and iron therapy have a place in the treatment of heart failure? Angiology 60(1):74\u201381","journal-title":"Angiology"},{"issue":"5","key":"2275_CR146","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.ahj.2007.07.034","volume":"154","author":"M Zilberman","year":"2007","unstructured":"Zilberman M et al (2007) Improvement of anemia with erythropoietin and intravenous iron reduces sleep-related breathing disorders and improves daytime sleepiness in anemic patients with congestive heart failure. Am Heart J 154(5):870\u2013876","journal-title":"Am Heart J"},{"issue":"6","key":"2275_CR147","doi-asserted-by":"publisher","first-page":"1096e9","DOI":"10.1016\/j.ahj.2006.08.005","volume":"152","author":"A Palazzuoli","year":"2006","unstructured":"Palazzuoli A et al (2006) Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am Heart J 152(6):1096e9-1115","journal-title":"Am Heart J"},{"issue":"1","key":"2275_CR148","doi-asserted-by":"publisher","first-page":"49","DOI":"10.7326\/0003-4819-157-1-201206190-00429","volume":"157","author":"JL Carson","year":"2012","unstructured":"Carson JL et al (2012) Red blood cell transfusion: a clinical practice guideline from the AABB*. Ann Intern Med 157(1):49\u201358","journal-title":"Ann Intern Med"},{"issue":"4","key":"2275_CR149","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1111\/trf.12903","volume":"55","author":"MP Robich","year":"2015","unstructured":"Robich MP et al (2015) Trends in blood utilization in United States cardiac surgical patients. Transfusion 55(4):805\u2013814","journal-title":"Transfusion"},{"issue":"2","key":"2275_CR150","first-page":"68","volume":"22","author":"A Petrou","year":"2018","unstructured":"Petrou A et al (2018) Mortality associated with standard prescription transfusions in cardiac surgery. Hippokratia 22(2):68\u201374","journal-title":"Hippokratia"},{"issue":"19","key":"2275_CR151","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1001\/jama.2016.9185","volume":"316","author":"JL Carson","year":"2016","unstructured":"Carson JL et al (2016) Clinical practice guidelines from the AABB: red blood cell transfusion thresholds and storage. JAMA 316(19):2025\u20132035","journal-title":"JAMA"},{"issue":"1","key":"2275_CR152","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13613-020-00727-y","volume":"10","author":"CU Nilsson","year":"2020","unstructured":"Nilsson CU et al (2020) Mortality and morbidity of low-grade red blood cell transfusions in septic patients: a propensity score-matched observational study of a liberal transfusion strategy. Ann Intensive Care 10(1):111","journal-title":"Ann Intensive Care"},{"issue":"8","key":"2275_CR153","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.jacc.2014.05.040","volume":"64","author":"AC Salisbury","year":"2014","unstructured":"Salisbury AC et al (2014) Blood transfusion during acute myocardial infarction: association with mortality and variability across hospitals. J Am Coll Cardiol 64(8):811\u2013819","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"2275_CR154","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1053\/j.jvca.2010.01.001","volume":"24","author":"AH van Straten","year":"2010","unstructured":"van Straten AH et al (2010) Risk factors for red blood cell transfusion after coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth 24(3):413\u2013417","journal-title":"J Cardiothorac Vasc Anesth"},{"issue":"1","key":"2275_CR155","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.amjcard.2010.08.046","volume":"107","author":"DP Kao","year":"2011","unstructured":"Kao DP et al (2011) Characteristics and outcomes among heart failure patients with anemia and renal insufficiency with and without blood transfusions (public discharge data from California 2000\u20132006). Am J Cardiol 107(1):69\u201373","journal-title":"Am J Cardiol"},{"key":"2275_CR156","volume":"10","author":"JL Carson","year":"2016","unstructured":"Carson JL et al (2016) Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev 10:CD002042","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"2275_CR157","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1186\/s13104-018-3988-z","volume":"11","author":"K Kristof","year":"2018","unstructured":"Kristof K et al (2018) Anaemia requiring red blood cell transfusion is associated with unfavourable 90-day survival in surgical patients with sepsis. BMC Res Notes 11(1):879","journal-title":"BMC Res Notes"},{"issue":"17","key":"2275_CR158","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1182\/blood-2018-08-833962","volume":"133","author":"CA Tormey","year":"2019","unstructured":"Tormey CA, Hendrickson JE (2019) Transfusion-related red blood cell alloantibodies: induction and consequences. Blood 133(17):1821\u20131830","journal-title":"Blood"},{"issue":"Suppl 1","key":"2275_CR159","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/anae.12892","volume":"70","author":"S Hart","year":"2015","unstructured":"Hart S, Cserti-Gazdewich CM, McCluskey SA (2015) Red cell transfusion and the immune system. Anaesthesia 70(Suppl 1):38\u201345 (e13\u20136)","journal-title":"Anaesthesia"},{"issue":"4","key":"2275_CR160","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1002\/ehf2.12237","volume":"4","author":"J Springer","year":"2017","unstructured":"Springer J, Springer JI, Anker SD (2017) Muscle wasting and sarcopenia in heart failure and beyond: update 2017. ESC Heart Fail 4(4):492\u2013498","journal-title":"ESC Heart Fail"},{"issue":"6","key":"2275_CR161","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.jchf.2018.03.014","volume":"6","author":"S Kinugawa","year":"2018","unstructured":"Kinugawa S, Fukushima A (2018) Malnutrition in heart failure: important but undervalued issue. JACC Heart Fail 6(6):487\u2013488","journal-title":"JACC Heart Fail"},{"issue":"5","key":"2275_CR162","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.pcad.2016.01.008","volume":"58","author":"CJ Lavie","year":"2016","unstructured":"Lavie CJ et al (2016) Obesity and prevalence of cardiovascular diseases and prognosis-the obesity paradox updated. Prog Cardiovasc Dis 58(5):537\u2013547","journal-title":"Prog Cardiovasc Dis"},{"issue":"5","key":"2275_CR163","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1097\/MCO.0b013e328363bcca","volume":"16","author":"A De Schutter","year":"2013","unstructured":"De Schutter A et al (2013) Obesity paradox and the heart: which indicator of obesity best describes this complex relationship? Curr Opin Clin Nutr Metab Care 16(5):517\u2013524","journal-title":"Curr Opin Clin Nutr Metab Care"},{"issue":"1","key":"2275_CR164","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1001\/jama.2015.17346","volume":"315","author":"DW Kitzman","year":"2016","unstructured":"Kitzman DW et al (2016) Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 315(1):36\u201346","journal-title":"JAMA"},{"issue":"4 Suppl 1","key":"2275_CR165","doi-asserted-by":"publisher","first-page":"S68","DOI":"10.1053\/ajkd.2001.27578","volume":"38","author":"JD Kopple","year":"2001","unstructured":"Kopple JD, National Kidney Foundation KDWG (2001) The National Kidney Foundation K\/DOQI clinical practice guidelines for dietary protein intake for chronic dialysis patients. Am J Kidney Dis 38(4 Suppl 1):S68-73","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"2275_CR166","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1161\/CIRCRESAHA.107.150417","volume":"101","author":"GD Lopaschuk","year":"2007","unstructured":"Lopaschuk GD, Folmes CD, Stanley WC (2007) Cardiac energy metabolism in obesity. Circ Res 101(4):335\u2013347","journal-title":"Circ Res"},{"issue":"Pt 1","key":"2275_CR167","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1113\/jphysiol.2003.055095","volume":"555","author":"R Ventura-Clapier","year":"2004","unstructured":"Ventura-Clapier R, Garnier A, Veksler V (2004) Energy metabolism in heart failure. J Physiol 555(Pt 1):1\u201313","journal-title":"J Physiol"},{"issue":"3","key":"2275_CR168","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1093\/cvr\/cvp414","volume":"86","author":"T Doenst","year":"2010","unstructured":"Doenst T et al (2010) Decreased rates of substrate oxidation ex vivo predict the onset of heart failure and contractile dysfunction in rats with pressure overload. Cardiovasc Res 86(3):461\u2013470","journal-title":"Cardiovasc Res"},{"issue":"5","key":"2275_CR169","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1161\/CIRCHEARTFAILURE.112.000228","volume":"6","author":"L Zhang","year":"2013","unstructured":"Zhang L et al (2013) Cardiac insulin-resistance and decreased mitochondrial energy production precede the development of systolic heart failure after pressure-overload hypertrophy. Circ Heart Fail 6(5):1039\u20131048","journal-title":"Circ Heart Fail"},{"issue":"5","key":"2275_CR170","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1172\/JCI0213946","volume":"109","author":"DD Belke","year":"2002","unstructured":"Belke DD et al (2002) Insulin signaling coordinately regulates cardiac size, metabolism, and contractile protein isoform expression. J Clin Invest 109(5):629\u2013639","journal-title":"J Clin Invest"},{"issue":"11","key":"2275_CR171","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.2337\/db13-0095","volume":"62","author":"Y Qi","year":"2013","unstructured":"Qi Y et al (2013) Myocardial loss of IRS1 and IRS2 causes heart failure and is controlled by p38alpha MAPK during insulin resistance. Diabetes 62(11):3887\u20133900","journal-title":"Diabetes"},{"issue":"7","key":"2275_CR172","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1161\/CIRCRESAHA.116.306206","volume":"118","author":"C Riehle","year":"2016","unstructured":"Riehle C, Abel ED (2016) Insulin signaling and heart failure. Circ Res 118(7):1151\u20131169","journal-title":"Circ Res"},{"issue":"4","key":"2275_CR173","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1161\/CIRCHEARTFAILURE.112.966705","volume":"5","author":"J Mori","year":"2012","unstructured":"Mori J et al (2012) Agonist-induced hypertrophy and diastolic dysfunction are associated with selective reduction in glucose oxidation: a metabolic contribution to heart failure with normal ejection fraction. Circ Heart Fail 5(4):493\u2013503","journal-title":"Circ Heart Fail"},{"issue":"10","key":"2275_CR174","doi-asserted-by":"publisher","first-page":"3824","DOI":"10.1210\/jc.2009-0719","volume":"94","author":"AJ Hanley","year":"2009","unstructured":"Hanley AJ et al (2009) Association of hematological parameters with insulin resistance and beta-cell dysfunction in nondiabetic subjects. J Clin Endocrinol Metab 94(10):3824\u20133832","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2275_CR175","doi-asserted-by":"publisher","first-page":"H2400","DOI":"10.1152\/ajpheart.01030.2004","volume":"288","author":"L Zhou","year":"2005","unstructured":"Zhou L et al (2005) Mechanistic model of cardiac energy metabolism predicts localization of glycolysis to cytosolic subdomain during ischemia. Am J Physiol Heart Circ Physiol 288(5):H2400\u2013H2411","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"5","key":"2275_CR176","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1053\/j.gastro.2009.01.048","volume":"136","author":"E Kirk","year":"2009","unstructured":"Kirk E et al (2009) Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction. Gastroenterology 136(5):1552\u20131560","journal-title":"Gastroenterology"},{"key":"2275_CR177","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1476-7120-9-43","volume":"9","author":"J Hlebowicz","year":"2011","unstructured":"Hlebowicz J et al (2011) The effect of endogenously released glucose, insulin, glucagon-like peptide 1, ghrelin on cardiac output, heart rate, stroke volume, and blood pressure. Cardiovasc Ultrasound 9:43","journal-title":"Cardiovasc Ultrasound"},{"issue":"3","key":"2275_CR178","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1093\/ajcn\/nqaa311","volume":"113","author":"S Sze","year":"2021","unstructured":"Sze S et al (2021) The impact of malnutrition on short-term morbidity and mortality in ambulatory patients with heart failure. Am J Clin Nutr 113(3):695\u2013705","journal-title":"Am J Clin Nutr"},{"issue":"8","key":"2275_CR179","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1007\/s00392-020-01774-y","volume":"110","author":"S Katano","year":"2021","unstructured":"Katano S et al (2021) Energy intake during hospital stay predicts all-cause mortality after discharge independently of nutritional status in elderly heart failure patients. Clin Res Cardiol 110(8):1202\u20131220","journal-title":"Clin Res Cardiol"},{"issue":"5","key":"2275_CR180","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1002\/ehf2.12501","volume":"6","author":"SC Chien","year":"2019","unstructured":"Chien SC et al (2019) Malnutrition in acute heart failure with preserved ejection fraction: clinical correlates and prognostic implications. ESC Heart Fail 6(5):953\u2013964","journal-title":"ESC Heart Fail"},{"issue":"1","key":"2275_CR181","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/1747-0080.12465","volume":"76","author":"H Matsuo","year":"2019","unstructured":"Matsuo H et al (2019) Risk of malnutrition is associated with poor physical function in patients undergoing cardiac rehabilitation following heart failure. Nutr Diet 76(1):82\u201388","journal-title":"Nutr Diet"},{"issue":"10","key":"2275_CR182","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/BF03028620","volume":"12","author":"S Chevalier","year":"2008","unstructured":"Chevalier S et al (2008) The physical functional capacity of frail elderly persons undergoing ambulatory rehabilitation is related to their nutritional status. J Nutr Health Aging 12(10):721\u2013726","journal-title":"J Nutr Health Aging"},{"issue":"5","key":"2275_CR183","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.cardfail.2019.03.007","volume":"25","author":"AR Vest","year":"2019","unstructured":"Vest AR et al (2019) Nutrition, obesity, and cachexia in patients with heart failure: a consensus statement from the heart failure society of America scientific statements committee. J Card Fail 25(5):380\u2013400","journal-title":"J Card Fail"},{"issue":"4","key":"2275_CR184","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1017\/S0029665115002438","volume":"74","author":"S von Haehling","year":"2015","unstructured":"von Haehling S (2015) The wasting continuum in heart failure: from sarcopenia to cachexia. Proc Nutr Soc 74(4):367\u2013377","journal-title":"Proc Nutr Soc"},{"issue":"5","key":"2275_CR185","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.jacbts.2017.06.009","volume":"2","author":"S Carbone","year":"2017","unstructured":"Carbone S et al (2017) Dietary fat, sugar consumption, and cardiorespiratory fitness in patients with heart failure with preserved ejection fraction. JACC Basic Transl Sci 2(5):513\u2013525","journal-title":"JACC Basic Transl Sci"},{"issue":"6","key":"2275_CR186","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1002\/jcsm.12839","volume":"12","author":"O Gungor","year":"2021","unstructured":"Gungor O et al (2021) Effects of hormonal changes on sarcopenia in chronic kidney disease: where are we now and what can we do? J Cachexia Sarcopenia Muscle 12(6):1380\u20131392","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"13","key":"2275_CR187","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1001\/archinte.166.13.1380","volume":"166","author":"L Ferrucci","year":"2006","unstructured":"Ferrucci L et al (2006) Low testosterone levels and the risk of anemia in older men and women. Arch Intern Med 166(13):1380\u20131388","journal-title":"Arch Intern Med"},{"key":"2275_CR188","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1146\/annurev-med-050219-034711","volume":"72","author":"M Rodrigues Dos Santos","year":"2021","unstructured":"Rodrigues Dos Santos M, Bhasin S (2021) Benefits and risks of testosterone treatment in men with age-related decline in testosterone. Annu Rev Med 72:75\u201391","journal-title":"Annu Rev Med"},{"key":"2275_CR189","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105758","volume":"171","author":"VE Bianchi","year":"2021","unstructured":"Bianchi VE et al (2021) The role of androgens in women\u2019s health and wellbeing. Pharmacol Res 171:105758","journal-title":"Pharmacol Res"},{"key":"2275_CR190","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1002\/ehf2.14117","volume":"10","author":"AM Marra","year":"2022","unstructured":"Marra AM et al (2022) Testosterone deficiency independently predicts mortality in women with HFrEF: insights from the T.O.S.CA. registry. ESC Heart Fail 10:159\u2013166","journal-title":"ESC Heart Fail"},{"issue":"16","key":"2275_CR191","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1016\/j.jacc.2010.03.090","volume":"56","author":"F Iellamo","year":"2010","unstructured":"Iellamo F et al (2010) Testosterone therapy in women with chronic heart failure: a pilot double-blind, randomized, placebo-controlled study. J Am Coll Cardiol 56(16):1310\u20131316","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2275_CR192","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1080\/13697137.2017.1291780","volume":"20","author":"GM Rosano","year":"2017","unstructured":"Rosano GM, Spoletini I, Vitale C (2017) Cardiovascular disease in women, is it different to men? The role of sex hormones. Climacteric 20(2):125\u2013128","journal-title":"Climacteric"},{"issue":"19","key":"2275_CR193","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.2174\/13816128113196660062","volume":"20","author":"M Maggio","year":"2014","unstructured":"Maggio M et al (2014) Multiple hormonal dysregulation as determinant of low physical performance and mobility in older persons. Curr Pharm Des 20(19):3119\u20133148","journal-title":"Curr Pharm Des"},{"issue":"2","key":"2275_CR194","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/j.1365-2605.1992.tb01118.x","volume":"15","author":"Y Hagenfeldt","year":"1992","unstructured":"Hagenfeldt Y et al (1992) Testosterone increases serum 1,25-dihydroxyvitamin D and insulin-like growth factor-I in hypogonadal men. Int J Androl 15(2):93\u2013102","journal-title":"Int J Androl"},{"issue":"20","key":"2275_CR195","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1001\/archinte.167.20.2249","volume":"167","author":"M Maggio","year":"2007","unstructured":"Maggio M et al (2007) Relationship between low levels of anabolic hormones and 6-year mortality in older men: the aging in the Chianti Area (InCHIANTI) study. Arch Intern Med 167(20):2249\u20132254","journal-title":"Arch Intern Med"},{"issue":"1","key":"2275_CR196","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.nefro.2016.04.009","volume":"37","author":"G Cobo","year":"2017","unstructured":"Cobo G et al (2017) Hypogonadism associated with muscle atrophy, physical inactivity and ESA hyporesponsiveness in men undergoing haemodialysis. Nefrologia 37(1):54\u201360","journal-title":"Nefrologia"},{"key":"2275_CR197","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3389\/fendo.2020.00033","volume":"11","author":"WJ Kraemer","year":"2020","unstructured":"Kraemer WJ et al (2020) Growth hormone(s), testosterone, insulin-like growth factors, and cortisol: roles and integration for cellular development and growth with exercise. Front Endocrinol (Lausanne) 11:33","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"7","key":"2275_CR198","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.1210\/en.2016-1150","volume":"157","author":"W Guo","year":"2016","unstructured":"Guo W et al (2016) Effects of testosterone on erythropoiesis in a female mouse model of anemia of inflammation. Endocrinology 157(7):2937\u20132946","journal-title":"Endocrinology"},{"issue":"3","key":"2275_CR199","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1182\/blood.V43.3.351.351","volume":"43","author":"AL Rosenblum","year":"1974","unstructured":"Rosenblum AL, Carbone PP (1974) Androgenic hormones and human granulopoiesis in vitro. Blood 43(3):351\u2013356","journal-title":"Blood"},{"issue":"981","key":"2275_CR200","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/206270a0","volume":"206","author":"EA Mirand","year":"1965","unstructured":"Mirand EA, Gordon AS, Wenig J (1965) Mechanism of testosterone action in erythropoiesis. Nature 206(981):270\u2013272","journal-title":"Nature"},{"issue":"3","key":"2275_CR201","first-page":"420","volume":"67","author":"W Fried","year":"1966","unstructured":"Fried W, Gurney CW (1966) The erythropoietic response to testosterone in male and female mice. J Lab Clin Med 67(3):420\u2013426","journal-title":"J Lab Clin Med"},{"issue":"5","key":"2275_CR202","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1182\/blood.V45.5.665.665","volume":"45","author":"Y Moriyama","year":"1975","unstructured":"Moriyama Y, Fisher JW (1975) Effects of testosterone and erythropoietin on erythroid colony formation in human bone marrow cultures. Blood 45(5):665\u2013670","journal-title":"Blood"},{"issue":"2","key":"2275_CR203","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1093\/ndt\/gfr288","volume":"27","author":"JJ Carrero","year":"2012","unstructured":"Carrero JJ et al (2012) Testosterone deficiency is a cause of anaemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease. Nephrol Dial Transplant 27(2):709\u2013715","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"2275_CR204","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1093\/ndt\/gfh638","volume":"20","author":"M DeLong","year":"2005","unstructured":"DeLong M et al (2005) Renin-angiotensin blockade reduces serum free testosterone in middle-aged men on haemodialysis and correlates with erythropoietin resistance. Nephrol Dial Transplant 20(3):585\u2013590","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"2275_CR205","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/andr.12622","volume":"8","author":"W Guo","year":"2020","unstructured":"Guo W et al (2020) Hepcidin is not essential for mediating testosterone\u2019s effects on erythropoiesis. Andrology 8(1):82\u201390","journal-title":"Andrology"},{"issue":"11","key":"2275_CR206","doi-asserted-by":"publisher","first-page":"3396","DOI":"10.1210\/clinem\/dgaa521","volume":"105","author":"AS Artz","year":"2020","unstructured":"Artz AS et al (2020) Markers of iron flux during testosterone-mediated erythropoiesis in older men with unexplained or iron-deficiency anemia. J Clin Endocrinol Metab 105(11):3396","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2275_CR207","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1210\/jc.2009-2575","volume":"95","author":"MM Fernandez-Balsells","year":"2010","unstructured":"Fernandez-Balsells MM et al (2010) Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 95(6):2560\u20132575","journal-title":"J Clin Endocrinol Metab"},{"issue":"5 Pt B","key":"2275_CR208","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1016\/j.bbadis.2017.08.029","volume":"1864","author":"WS Lee","year":"2018","unstructured":"Lee WS, Kim J (2018) Insulin-like growth factor-1 signaling in cardiac aging. Biochim Biophys Acta Mol Basis Dis 1864(5 Pt B):1931\u20131938","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"11","key":"2275_CR209","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.4158\/EP14100.OR","volume":"21","author":"F De Vita","year":"2015","unstructured":"De Vita F et al (2015) Insulin-like growth factor-1 and anemia in older subjects: the Inchianti study. Endocr Pract 21(11):1211\u20131218","journal-title":"Endocr Pract"},{"issue":"1","key":"2275_CR210","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/acel.12400","volume":"15","author":"L Fontana","year":"2016","unstructured":"Fontana L et al (2016) Effects of 2-year calorie restriction on circulating levels of IGF-1, IGF-binding proteins and cortisol in nonobese men and women: a randomized clinical trial. Aging Cell 15(1):22\u201327","journal-title":"Aging Cell"},{"key":"2275_CR211","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2019.100910","volume":"53","author":"J Rahmani","year":"2019","unstructured":"Rahmani J et al (2019) The influence of fasting and energy restricting diets on IGF-1 levels in humans: a systematic review and meta-analysis. Ageing Res Rev 53:100910","journal-title":"Ageing Res Rev"},{"key":"2275_CR212","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/978-981-10-4304-8_12","volume":"1000","author":"KL Weeks","year":"2017","unstructured":"Weeks KL et al (2017) The IGF1-PI3K-Akt signaling pathway in mediating exercise-induced cardiac hypertrophy and protection. Adv Exp Med Biol 1000:187\u2013210","journal-title":"Adv Exp Med Biol"},{"issue":"3","key":"2275_CR213","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1080\/10428190290011958","volume":"43","author":"W Zumkeller","year":"2002","unstructured":"Zumkeller W (2002) The insulin-like growth factor system in hematopoietic cells. Leuk Lymphoma 43(3):487\u2013491","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2275_CR214","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1172\/JCI115327","volume":"88","author":"SL Abboud","year":"1991","unstructured":"Abboud SL, Bethel CR, Aron DC (1991) Secretion of insulinlike growth factor I and insulinlike growth factor-binding proteins by murine bone marrow stromal cells. J Clin Invest 88(2):470\u2013475","journal-title":"J Clin Invest"},{"issue":"1","key":"2275_CR215","first-page":"3","volume":"16","author":"JI Jones","year":"1995","unstructured":"Jones JI, Clemmons DR (1995) Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 16(1):3\u201334","journal-title":"Endocr Rev"},{"issue":"1","key":"2275_CR216","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1172\/JCI117327","volume":"94","author":"K Muta","year":"1994","unstructured":"Muta K et al (1994) Distinct roles of erythropoietin, insulin-like growth factor I, and stem cell factor in the development of erythroid progenitor cells. J Clin Invest 94(1):34\u201343","journal-title":"J Clin Invest"},{"issue":"2","key":"2275_CR217","first-page":"447","volume":"74","author":"S Merchav","year":"1992","unstructured":"Merchav S et al (1992) Comparative studies of the erythroid-potentiating effects of biosynthetic human insulin-like growth factors-I and -II. J Clin Endocrinol Metab 74(2):447\u2013452","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2275_CR218","first-page":"1806","volume":"86","author":"SA Weinzimer","year":"2001","unstructured":"Weinzimer SA et al (2001) Transferrin is an insulin-like growth factor-binding protein-3 binding protein. J Clin Endocrinol Metab 86(4):1806\u20131813","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2275_CR219","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1182\/blood-2004-07-2599","volume":"105","author":"L Ferrucci","year":"2005","unstructured":"Ferrucci L et al (2005) The origins of age-related proinflammatory state. Blood 105(6):2294\u20132299","journal-title":"Blood"},{"issue":"1","key":"2275_CR220","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ymthe.2018.10.020","volume":"27","author":"A Heinen","year":"2019","unstructured":"Heinen A et al (2019) IGF1 treatment improves cardiac remodeling after infarction by targeting myeloid cells. Mol Ther 27(1):46\u201358","journal-title":"Mol Ther"},{"issue":"4","key":"2275_CR221","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.hfc.2018.05.002","volume":"14","author":"A Salzano","year":"2018","unstructured":"Salzano A et al (2018) Growth hormone therapy in heart failure. Heart Fail Clin 14(4):501\u2013515","journal-title":"Heart Fail Clin"},{"issue":"7","key":"2275_CR222","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1210\/clinem\/dgac199","volume":"107","author":"G Johannsson","year":"2022","unstructured":"Johannsson G et al (2022) Long-term safety of growth hormone in adults with growth hormone deficiency: overview of 15 809 GH-treated patients. J Clin Endocrinol Metab 107(7):1906\u20131919","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2275_CR223","doi-asserted-by":"publisher","first-page":"483","DOI":"10.2174\/1568026043451311","volume":"4","author":"KP Marathias","year":"2004","unstructured":"Marathias KP et al (2004) Hematocrit-lowering effect following inactivation of renin-angiotensin system with angiotensin converting enzyme inhibitors and angiotensin receptor blockers. Curr Top Med Chem 4(4):483\u2013486","journal-title":"Curr Top Med Chem"},{"issue":"7","key":"2275_CR224","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1055\/s-0032-1306286","volume":"120","author":"AE Raptis","year":"2012","unstructured":"Raptis AE et al (2012) Anemia due to coadministration of renin-angiotensin-system inhibitors and PPARgamma agonists in uncomplicated diabetic patients. Exp Clin Endocrinol Diabetes 120(7):416\u2013419","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"Suppl 3","key":"2275_CR225","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1097\/00005344-198900133-00007","volume":"13","author":"K Onoyama","year":"1989","unstructured":"Onoyama K et al (1989) Worsening of anemia by angiotensin converting enzyme inhibitors and its prevention by antiestrogenic steroid in chronic hemodialysis patients. J Cardiovasc Pharmacol 13(Suppl 3):S27-30","journal-title":"J Cardiovasc Pharmacol"},{"issue":"4","key":"2275_CR226","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/j.1365-2125.1992.tb05644.x","volume":"34","author":"MC Pratt","year":"1992","unstructured":"Pratt MC et al (1992) Effect of angiotensin converting enzyme inhibitors on erythropoietin concentrations in healthy volunteers. Br J Clin Pharmacol 34(4):363\u2013365","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"2275_CR227","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/ki.1996.398","volume":"50","author":"J Gossmann","year":"1996","unstructured":"Gossmann J et al (1996) Mechanism of angiotensin converting enzyme inhibitor-related anemia in renal transplant recipients. Kidney Int 50(3):973\u2013978","journal-title":"Kidney Int"},{"issue":"1","key":"2275_CR228","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1182\/blood-2004-04-1570","volume":"105","author":"K Savary","year":"2005","unstructured":"Savary K et al (2005) Role of the renin-angiotensin system in primitive erythropoiesis in the chick embryo. Blood 105(1):103\u2013110","journal-title":"Blood"},{"key":"2275_CR229","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/bs.vh.2017.02.001","volume":"105","author":"YC Kim","year":"2017","unstructured":"Kim YC, Mungunsukh O, Day RM (2017) Erythropoietin regulation by angiotensin II. Vitam Horm 105:57\u201377","journal-title":"Vitam Horm"},{"issue":"4","key":"2275_CR230","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/S1388-9842(01)00174-X","volume":"3","author":"E Erdmann","year":"2001","unstructured":"Erdmann E et al (2001) Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. Eur J Heart Fail 3(4):469\u2013479","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"2275_CR231","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.surg.2017.06.001","volume":"162","author":"S Hasan","year":"2017","unstructured":"Hasan S et al (2017) Discrete beta-adrenergic mechanisms regulate early and late erythropoiesis in erythropoietin-resistant anemia. Surgery 162(4):901\u2013916","journal-title":"Surgery"},{"issue":"2","key":"2275_CR232","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1093\/jbcr\/iraa150","volume":"42","author":"J Walczak","year":"2021","unstructured":"Walczak J et al (2021) Transient improvement in erythropoiesis is achieved via the chaperone AHSP with early administration of propranolol in burn patients. J Burn Care Res 42(2):311\u2013322","journal-title":"J Burn Care Res"},{"issue":"10","key":"2275_CR233","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1111\/j.1537-2995.2012.03609.x","volume":"52","author":"NE Glass","year":"2012","unstructured":"Glass NE et al (2012) The impact of beta-blocker therapy on anemia after traumatic brain injury. Transfusion 52(10):2155\u20132160","journal-title":"Transfusion"},{"issue":"5","key":"2275_CR234","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/j.amjsurg.2020.06.058","volume":"220","author":"ES Miller","year":"2020","unstructured":"Miller ES et al (2020) The effects of selective beta-adrenergic blockade on bone marrow dysfunction following severe trauma and chronic stress. Am J Surg 220(5):1312\u20131318","journal-title":"Am J Surg"},{"issue":"12","key":"2275_CR235","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1136\/hrt.2005.083998","volume":"92","author":"W Khan","year":"2006","unstructured":"Khan W et al (2006) Beta blocker treatment is associated with improvement in renal function and anaemia in patients with heart failure. Heart 92(12):1856\u20131857","journal-title":"Heart"},{"issue":"4","key":"2275_CR236","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/ejhf.2132","volume":"23","author":"KF Docherty","year":"2021","unstructured":"Docherty KF et al (2021) Effect of dapagliflozin on anaemia in DAPA-HF. Eur J Heart Fail 23(4):617\u2013628","journal-title":"Eur J Heart Fail"},{"issue":"24","key":"2275_CR237","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380(24):2295\u20132306","journal-title":"N Engl J Med"},{"issue":"5","key":"2275_CR238","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1159\/000507272","volume":"51","author":"KP Marathias","year":"2020","unstructured":"Marathias KP et al (2020) Competing effects of renin angiotensin system blockade and sodium-glucose cotransporter-2 inhibitors on erythropoietin secretion in diabetes. Am J Nephrol 51(5):349\u2013356","journal-title":"Am J Nephrol"},{"issue":"4","key":"2275_CR239","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa057","volume":"105","author":"H Ghanim","year":"2020","unstructured":"Ghanim H et al (2020) Dapagliflozin suppresses hepcidin and increases erythropoiesis. J Clin Endocrinol Metab 105(4):e1056","journal-title":"J Clin Endocrinol Metab"},{"issue":"15","key":"2275_CR240","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M et al (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383(15):1413\u20131424","journal-title":"N Engl J Med"},{"issue":"10","key":"2275_CR241","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1136\/heartjnl-2014-306596","volume":"101","author":"MG Wilson","year":"2015","unstructured":"Wilson MG, Ellison GM, Cable NT (2015) Basic science behind the cardiovascular benefits of exercise. Heart 101(10):758\u2013765","journal-title":"Heart"},{"issue":"1","key":"2275_CR242","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/cphy.c180004","volume":"9","author":"D Montero","year":"2018","unstructured":"Montero D, Lundby C (2018) Regulation of red blood cell volume with exercise training. Compr Physiol 9(1):149\u2013164","journal-title":"Compr Physiol"},{"key":"2275_CR243","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12890-015-0050-y","volume":"15","author":"M Ferrari","year":"2015","unstructured":"Ferrari M et al (2015) Anemia and hemoglobin serum levels are associated with exercise capacity and quality of life in chronic obstructive pulmonary disease. BMC Pulm Med 15:58","journal-title":"BMC Pulm Med"},{"issue":"1","key":"2275_CR244","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1006\/scdb.2001.0285","volume":"13","author":"S Rafii","year":"2002","unstructured":"Rafii S et al (2002) Contribution of marrow-derived progenitors to vascular and cardiac regeneration. Semin Cell Dev Biol 13(1):61\u201367","journal-title":"Semin Cell Dev Biol"},{"issue":"7","key":"2275_CR245","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/sms.12798","volume":"27","author":"D Montero","year":"2017","unstructured":"Montero D, Lundby C (2017) Red cell volume response to exercise training: association with aging. Scand J Med Sci Sports 27(7):674\u2013683","journal-title":"Scand J Med Sci Sports"},{"key":"2275_CR246","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.exger.2017.05.016","volume":"109","author":"DG Jakovljevic","year":"2018","unstructured":"Jakovljevic DG (2018) Physical activity and cardiovascular aging: physiological and molecular insights. Exp Gerontol 109:67\u201374","journal-title":"Exp Gerontol"},{"issue":"4","key":"2275_CR247","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1152\/japplphysiol.00164.2004","volume":"98","author":"AM Petersen","year":"2005","unstructured":"Petersen AM, Pedersen BK (2005) The anti-inflammatory effect of exercise. J Appl Physiol (1985) 98(4):1154\u20131162","journal-title":"J Appl Physiol (1985)"},{"issue":"2","key":"2275_CR248","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1080\/08830185.2019.1682569","volume":"39","author":"N Collao","year":"2020","unstructured":"Collao N et al (2020) Anti-inflammatory effect of exercise mediated by toll-like receptor regulation in innate immune cells\u2014a review. Int Rev Immunol 39(2):39\u201352","journal-title":"Int Rev Immunol"},{"issue":"7","key":"2275_CR249","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1080\/02640414.2020.1735684","volume":"38","author":"G Thompson","year":"2020","unstructured":"Thompson G et al (2020) Exercise and inflammation in coronary artery disease: a systematic review and meta-analysis of randomised trials. J Sports Sci 38(7):814\u2013826","journal-title":"J Sports Sci"},{"issue":"2 Pt 2","key":"2275_CR250","first-page":"R375","volume":"266","author":"SK Powers","year":"1994","unstructured":"Powers SK et al (1994) Influence of exercise and fiber type on antioxidant enzyme activity in rat skeletal muscle. Am J Physiol 266(2 Pt 2):R375\u2013R380","journal-title":"Am J Physiol"},{"issue":"1","key":"2275_CR251","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1038\/s41598-021-81736-0","volume":"11","author":"T Yokota","year":"2021","unstructured":"Yokota T et al (2021) Systemic oxidative stress is associated with lower aerobic capacity and impaired skeletal muscle energy metabolism in heart failure patients. Sci Rep 11(1):2272","journal-title":"Sci Rep"},{"issue":"23","key":"2275_CR252","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1001\/jama.283.23.3095","volume":"283","author":"R Hambrecht","year":"2000","unstructured":"Hambrecht R et al (2000) Effects of exercise training on left ventricular function and peripheral resistance in patients with chronic heart failure: a randomized trial. JAMA 283(23):3095\u20133101","journal-title":"JAMA"},{"issue":"1","key":"2275_CR253","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/ejhf.1838","volume":"23","author":"S von Haehling","year":"2021","unstructured":"von Haehling S et al (2021) Improving exercise capacity and quality of life using non-invasive heart failure treatments: evidence from clinical trials. Eur J Heart Fail 23(1):92\u2013113","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"2275_CR254","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/S0735-1097(97)00015-6","volume":"29","author":"R Hambrecht","year":"1997","unstructured":"Hambrecht R et al (1997) Effects of endurance training on mitochondrial ultrastructure and fiber type distribution in skeletal muscle of patients with stable chronic heart failure. J Am Coll Cardiol 29(5):1067\u20131073","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"2275_CR255","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1161\/CIRCHEARTFAILURE.109.868992","volume":"3","author":"S Erbs","year":"2010","unstructured":"Erbs S et al (2010) Exercise training in patients with advanced chronic heart failure (NYHA IIIb) promotes restoration of peripheral vasomotor function, induction of endogenous regeneration, and improvement of left ventricular function. Circ Heart Fail 3(4):486\u2013494","journal-title":"Circ Heart Fail"},{"issue":"3","key":"2275_CR256","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1001\/jama.2008.1022","volume":"301","author":"J Grewal","year":"2009","unstructured":"Grewal J et al (2009) Left ventricular function and exercise capacity. JAMA 301(3):286\u2013294","journal-title":"JAMA"},{"issue":"4","key":"2275_CR257","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/S1071-9164(99)91334-9","volume":"5","author":"R Tyni-Lenne","year":"1999","unstructured":"Tyni-Lenne R et al (1999) Aerobic training involving a minor muscle mass shows greater efficiency than training involving a major muscle mass in chronic heart failure patients. J Card Fail 5(4):300\u2013307","journal-title":"J Card Fail"},{"issue":"1","key":"2275_CR258","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/PHM.0000000000000312","volume":"95","author":"TC Fu","year":"2016","unstructured":"Fu TC et al (2016) Aerobic interval training elicits different hemodynamic adaptations between heart failure patients with preserved and reduced ejection fraction. Am J Phys Med Rehabil 95(1):15\u201327","journal-title":"Am J Phys Med Rehabil"},{"issue":"10","key":"2275_CR259","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1249\/00005768-199310000-00009","volume":"25","author":"D Criswell","year":"1993","unstructured":"Criswell D et al (1993) High intensity training-induced changes in skeletal muscle antioxidant enzyme activity. Med Sci Sports Exerc 25(10):1135\u20131140","journal-title":"Med Sci Sports Exerc"},{"issue":"13","key":"2275_CR260","doi-asserted-by":"publisher","first-page":"6761","DOI":"10.3390\/ijerph18136761","volume":"18","author":"D Li","year":"2021","unstructured":"Li D, Chen P, Zhu J (2021) The effects of interval training and continuous training on cardiopulmonary fitness and exercise tolerance of patients with heart failure\u2014a systematic review and meta-analysis. Int J Environ Res Public Health 18(13):6761","journal-title":"Int J Environ Res Public Health"},{"issue":"7","key":"2275_CR261","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1016\/S0735-1097(97)82540-5","volume":"29","author":"P Dubach","year":"1997","unstructured":"Dubach P et al (1997) Effect of high intensity exercise training on central hemodynamic responses to exercise in men with reduced left ventricular function. J Am Coll Cardiol 29(7):1591\u20131598","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"2275_CR262","doi-asserted-by":"publisher","first-page":"3086","DOI":"10.1161\/CIRCULATIONAHA.106.675041","volume":"115","author":"U Wisloff","year":"2007","unstructured":"Wisloff U et al (2007) Superior cardiovascular effect of aerobic interval training versus moderate continuous training in heart failure patients: a randomized study. Circulation 115(24):3086\u20133094","journal-title":"Circulation"},{"issue":"6","key":"2275_CR263","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1751-7133.2012.00295.x","volume":"18","author":"NA Smart","year":"2012","unstructured":"Smart NA et al (2012) Exercise training in heart failure with preserved systolic function: a randomized controlled trial of the effects on cardiac function and functional capacity. Congest Heart Fail 18(6):295\u2013301","journal-title":"Congest Heart Fail"},{"issue":"24","key":"2275_CR264","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1016\/j.jacc.2007.02.055","volume":"49","author":"MJ Haykowsky","year":"2007","unstructured":"Haykowsky MJ et al (2007) A meta-analysis of the effect of exercise training on left ventricular remodeling in heart failure patients: the benefit depends on the type of training performed. J Am Coll Cardiol 49(24):2329\u20132336","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"2275_CR265","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/j.jacc.2005.12.050","volume":"47","author":"C Passino","year":"2006","unstructured":"Passino C et al (2006) Aerobic training decreases B-type natriuretic peptide expression and adrenergic activation in patients with heart failure. J Am Coll Cardiol 47(9):1835\u20131839","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2275_CR266","first-page":"130","volume":"26","author":"K Villelabeitia-Jaureguizar","year":"2019","unstructured":"Villelabeitia-Jaureguizar K et al (2019) Mechanical efficiency of high versus moderate intensity aerobic exercise in coronary heart disease patients: a randomized clinical trial. Cardiol J 26(2):130\u2013137","journal-title":"Cardiol J"},{"issue":"6","key":"2275_CR267","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1152\/japplphysiol.00518.2014","volume":"119","author":"SS Angadi","year":"2015","unstructured":"Angadi SS et al (2015) High-intensity interval training vs. moderate-intensity continuous exercise training in heart failure with preserved ejection fraction: a pilot study. J Appl Physiol (1985) 119(6):753\u2013758","journal-title":"J Appl Physiol (1985)"},{"issue":"4","key":"2275_CR268","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/j.1751-7133.2011.00274.x","volume":"18","author":"NA Smart","year":"2012","unstructured":"Smart NA, Steele M (2012) A comparison of 16 weeks of continuous vs intermittent exercise training in chronic heart failure patients. Congest Heart Fail 18(4):205\u2013211","journal-title":"Congest Heart Fail"},{"issue":"6","key":"2275_CR269","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1016\/j.ijcard.2012.06.057","volume":"167","author":"F Iellamo","year":"2013","unstructured":"Iellamo F et al (2013) Matched dose interval and continuous exercise training induce similar cardiorespiratory and metabolic adaptations in patients with heart failure. Int J Cardiol 167(6):2561\u20132565","journal-title":"Int J Cardiol"},{"issue":"9","key":"2275_CR270","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1161\/CIRCULATIONAHA.116.022924","volume":"135","author":"O Ellingsen","year":"2017","unstructured":"Ellingsen O et al (2017) High-intensity interval training in patients with heart failure with reduced ejection fraction. Circulation 135(9):839\u2013849","journal-title":"Circulation"},{"key":"2275_CR271","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/ejhf.1838","volume":"23","author":"S von Haehling","year":"2020","unstructured":"von Haehling S et al (2020) Improving exercise capacity and quality of life using non-invasive heart failure treatments: evidence from clinical trials. Eur J Heart Fail 23:92\u2013113","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"2275_CR272","doi-asserted-by":"publisher","first-page":"352","DOI":"10.23736\/S0022-4707.18.07865-9","volume":"59","author":"IE Zelenkova","year":"2019","unstructured":"Zelenkova IE et al (2019) Relationship between total hemoglobin mass and competitive performance in endurance athletes. J Sports Med Phys Fitness 59(3):352\u2013356","journal-title":"J Sports Med Phys Fitness"},{"issue":"2","key":"2275_CR273","doi-asserted-by":"publisher","first-page":"H434","DOI":"10.1152\/ajpheart.00164.2019","volume":"317","author":"JC Craig","year":"2019","unstructured":"Craig JC et al (2019) Central and peripheral factors mechanistically linked to exercise intolerance in heart failure with reduced ejection fraction. Am J Physiol Heart Circ Physiol 317(2):H434\u2013H444","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"4","key":"2275_CR274","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1002\/cphy.c110065","volume":"2","author":"TL Haas","year":"2012","unstructured":"Haas TL et al (2012) Exercise training and peripheral arterial disease. Compr Physiol 2(4):2933\u20133017","journal-title":"Compr Physiol"},{"issue":"1","key":"2275_CR275","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/S0002-9149(83)80010-1","volume":"51","author":"MB Higginbotham","year":"1983","unstructured":"Higginbotham MB et al (1983) Determinants of variable exercise performance among patients with severe left ventricular dysfunction. Am J Cardiol 51(1):52\u201360","journal-title":"Am J Cardiol"},{"issue":"4","key":"2275_CR276","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1080\/13685538.2016.1229764","volume":"19","author":"YS Shin","year":"2016","unstructured":"Shin YS et al (2016) The relationship between serum total testosterone and free testosterone levels with serum hemoglobin and hematocrit levels: a study in 1221 men. Aging Male 19(4):209\u2013214","journal-title":"Aging Male"},{"issue":"7","key":"2275_CR277","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.2337\/diacare.28.7.1636","volume":"28","author":"N Pitteloud","year":"2005","unstructured":"Pitteloud N et al (2005) Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care 28(7):1636\u20131642","journal-title":"Diabetes Care"},{"issue":"5","key":"2275_CR278","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s10741-018-9721-0","volume":"23","author":"VE Bianchi","year":"2018","unstructured":"Bianchi VE (2018) Testosterone, myocardial function, and mortality. Heart Fail Rev 23(5):773\u2013788","journal-title":"Heart Fail Rev"},{"issue":"11","key":"2275_CR279","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1093\/gerona\/58.11.M1002","volume":"58","author":"S Bhasin","year":"2003","unstructured":"Bhasin S (2003) Testosterone supplementation for aging-associated sarcopenia. J Gerontol A Biol Sci Med Sci 58(11):1002\u20131008","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"12","key":"2275_CR280","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/S2213-8587(15)00284-3","volume":"3","author":"SR Davis","year":"2015","unstructured":"Davis SR, Wahlin-Jacobsen S (2015) Testosterone in women\u2013the clinical significance. Lancet Diabetes Endocrinol 3(12):980\u2013992","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"2275_CR281","doi-asserted-by":"publisher","first-page":"4660","DOI":"10.1210\/jc.2019-01603","volume":"104","author":"SR Davis","year":"2019","unstructured":"Davis SR et al (2019) Global consensus position statement on the use of testosterone therapy for women. J Clin Endocrinol Metab 104(10):4660\u20134666","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2275_CR282","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1038\/s41591-019-0633-x","volume":"25","author":"V Frodermann","year":"2019","unstructured":"Frodermann V et al (2019) Exercise reduces inflammatory cell production and cardiovascular inflammation via instruction of hematopoietic progenitor cells. Nat Med 25(11):1761\u20131771","journal-title":"Nat Med"},{"key":"2275_CR283","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.117630","volume":"252","author":"A Thirupathi","year":"2020","unstructured":"Thirupathi A, Pinho RA, Chang YZ (2020) Physical exercise: an inducer of positive oxidative stress in skeletal muscle aging. Life Sci 252:117630","journal-title":"Life Sci"},{"issue":"8","key":"2275_CR284","doi-asserted-by":"publisher","first-page":"649","DOI":"10.2165\/00007256-200535080-00001","volume":"35","author":"MS El-Sayed","year":"2005","unstructured":"El-Sayed MS, Ali N, El-Sayed Ali Z (2005) Haemorheology in exercise and training. Sports Med 35(8):649\u2013670","journal-title":"Sports Med"},{"key":"2275_CR285","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/bs.vh.2017.04.001","volume":"105","author":"MP Zafeiriou","year":"2017","unstructured":"Zafeiriou MP (2017) The erythropoietin system protects the heart upon injury by cardiac progenitor cell activation. Vitam Horm 105:233\u2013248","journal-title":"Vitam Horm"},{"issue":"4","key":"2275_CR286","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1210\/er.2017-00025","volume":"38","author":"AL Goldman","year":"2017","unstructured":"Goldman AL et al (2017) A reappraisal of testosterone\u2019s binding in circulation: physiological and clinical implications. Endocr Rev 38(4):302\u2013324","journal-title":"Endocr Rev"},{"issue":"3","key":"2275_CR287","doi-asserted-by":"publisher","first-page":"R47","DOI":"10.1530\/JOE-12-0582","volume":"217","author":"DM Kelly","year":"2013","unstructured":"Kelly DM, Jones TH (2013) Testosterone: a vascular hormone in health and disease. J Endocrinol 217(3):R47-71","journal-title":"J Endocrinol"},{"issue":"2","key":"2275_CR288","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s13105-016-0545-x","volume":"73","author":"VJ Lara-Diaz","year":"2017","unstructured":"Lara-Diaz VJ et al (2017) IGF-1 modulates gene expression of proteins involved in inflammation, cytoskeleton, and liver architecture. J Physiol Biochem 73(2):245\u2013258","journal-title":"J Physiol Biochem"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-023-02275-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-023-02275-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-023-02275-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T14:18:28Z","timestamp":1721830708000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-023-02275-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,3]]},"references-count":288,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["2275"],"URL":"https:\/\/doi.org\/10.1007\/s00392-023-02275-4","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,3]]},"assertion":[{"value":"22 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SvH has been a paid consultant for and\/or received honoraria payments from AstraZeneca, Bayer, Boehringer Ingelheim, BRAHMS, Chugai, Gr\u00fcnenthal, Helsinn, Hexal, Novartis, Pharmacosmos, Respicardia, Roche, Servier, Sorin, and Vifor. SvH reports research support from Amgen, Boehringer Ingelheim, IMI, and the German Center for Cardiovascular Research (DZHK). VB has no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}